Abeona Therapeutics, Inc.
(NASDAQ : ABEO)

( )
ABEO PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Generic
symbolcompany%chnglast%shortavg$volume
AGNAllergan plc
-0.20%166.012.9%$476.36m
ZTSZoetis, Inc. Class A
-0.61%120.951.9%$227.16m
TEVATeva Pharmaceutical Industries Limited Sponsored ADR
-3.06%7.932.0%$173.28m
MYLMylan N.V.
-2.47%21.693.2%$107.10m
TXMDTherapeuticsMD, Inc.
2.09%3.4224.9%$8.00m
RDYDr. Reddy's Laboratories Ltd. Sponsored ADR
-1.12%38.782.0%$6.36m
ABEOAbeona Therapeutics, Inc.
-5.41%2.977.6%$5.55m
TAROTaro Pharmaceutical Industries Ltd.
2.46%81.806.4%$4.93m
JAGXJaguar Animal Health, Inc.
0.00%1.339.8%$2.26m
KINKindred Biosciences, Inc.
13.74%8.030.3%$1.11m
LFVNLifeVantage Corporation
-1.50%13.103.3%$0.96m
CPHIChina Pharma Holdings, Inc.
0.71%0.270.1%$0.04m

Company Profile

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.